-
You said that the monthly salary of pharmaceutical companies is tens of thousands, but I can't afford to hire a nurse with a daily salary of 220...
Time of Update: 2021-05-22
Anyway, as a pharmaceutical professional for many years, I regret that my salary has lowered the national average income.
But in pharmaceutical companies, how many people who work within three years can get a daily salary of 200?
-
Chengdu Xiandao HG146 Capsule New Indication Clinical Trial Application Approved
Time of Update: 2021-05-22
Recently, Chengdu Pilot issued an announcement stating that the company has received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration, and the company's research project "HG146 Capsules" (hereinafter referred to as "HG146") has been applied for clinical trials for expanding indications.
-
New drugs for Roche's hemophilia and neuromyelitis optica spectrum disorder approved in China
Time of Update: 2021-05-22
The drugs approved this time are iimerizumab for hemophilia A patients and satralizumab for NMOSD patients.
It is understood that iimerizumab is the first preventive drug for hemophilia A with or without coagulation factor VIII inhibitor in the body; satralizumab is the first subcutaneous treatment of Aquaporin-4 (AQP4) antibody-positive NMOSD drug .
-
Astellas' new hormone-sensitive prostate cancer drug Xtandi receives EU approval for its new indication
Time of Update: 2021-05-22
Recently, Astellas announced that the European Commission has approved a new indication for Xtandi: for the treatment of adult patients with metastatic hormone-sensitive prostate cancer.
Original source: Astellas' XTANDI (enzalutamide) approved by European Commission for Men with Metastatic Hormone-Sensitive Prostate Cancer
-
SSGJ-612 Clinical Trial Approved for Injection
Time of Update: 2021-05-22
Its product "SSGJ-612 for injection" will start clinical trials in the near future.
. SSGJ-612 evolved on the classic HER2 receptor.
Studies have shown that SSGJ-612 may inhibit the growth of HER2-positive tumor cells in a completely different way than trastuzumab and pertuzumab.
-
Media: US 70 million doses of Johnson & Johnson vaccine may be scrapped due to pollution
Time of Update: 2021-05-22
On May 7, the New York Times reported that Johnson & Johnson's 70 million doses of new crown vaccine may be scrapped due to pollution.
-
Another round of "big chaos" among pharmaceutical companies is coming, involving 53 varieties!
Time of Update: 2021-05-22
In this "Chongqing, Henan, Hubei, Xianggui, Qiongyun, Qingning Xinxin Xinjiang Corps Report on Drug Submissions to Alliance Provinces (Cities, Districts) In the "Notice of Volume Procurement Related Data", there are 53 varieties in the report list, and the report starts on the first day of work after the holiday.
-
Prism Pharmaceuticals obtains New Zealand marketing authorization
Time of Update: 2021-05-22
Community-acquired pneumoniaPatients who are caused by pathogenic bacteria such as Chlamydia pneumoniae, Haemophilus influenzae, Legionella pneumophila, Moraxella catarrhalis, Mycoplasma pneumoniae, Staphylococcus aureus, or Streptococcus pneumoniae, and whose initial treatment requires intravenous administration.
Bacterial culture and drug susceptibility test should be carried out before administration to find out the pathogenic bacteria and its sensitivity to azithromycin.
-
Zhao Yanping, vice president of Beijing Tide Pharmaceuticals, won the honor of "National May 1st Labor Medal"
Time of Update: 2021-05-22
It is reported that a total of three people in Beijing Economic and Technological Development Zone won the 2021 National May 1st Labor Medal.
-
Announcement of the list of negotiated drug allocation agencies
Time of Update: 2021-05-22
It is understood that, in order to facilitate the timely purchase of drugs for the national medical insurance negotiations, the National Medical Insurance Administration organized experts to screen the first batch of 19 drugs with urgent clinical needs and not strong substitutes from the newly negotiated drugs in 2020.
-
GSK's first-quarter results failed to meet expectations, and more anti-cancer drug investment will be reduced in the future
Time of Update: 2021-05-22
In the first quarter report, GSK revealed that due to the priority of its product portfolio, the company will abandon the phase I development plan of DMD's hematopoietic prostaglandin D2 synthase inhibitor GSK3439171 and the oncology drug candidate GSK3537142 in cooperation with Immunocore.
-
Roche CEO joins alliance against abandoning COVID vaccine patents
Time of Update: 2021-05-21
"Earlier this month, the Biden government unexpectedly took an action to support a proposal made by the World Trade Organization (WTO) that would temporarily suspend patent rights for COVID-19 products.
-
Hengrui SHR-1905 was approved as the third monoclonal antibody in the field of clinical asthma
Time of Update: 2021-05-21
The curative effect of existing biological drugs is associated with increased eosinophil content, which is observed in 60% of patients with moderate to severe asthma.
According to the Insight database, AstraZeneca has currently carried out a phase III clinical trial of Tezepelumab for asthma in China.
-
Generic Ochinib is here!
Time of Update: 2021-05-21
In March 2017, the National Medical Products Administration (NMPA) approved the third-generation lung cancer targeted drug Teresa® (osimertinib mesylate tablets, AZD9291) for the past transepidermal growth factor receptor (EGFR) tyrosine Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have disease progression during or after treatment with TKI, and confirmed to have EGFR T790M mutation-positive.
-
Wanchun Pharmaceutical's "Punabulin" reported to be listed in the priority review
Time of Update: 2021-05-21
In addition, Plinabulin is a non-G-CSF drug that reverses the blocking formation of neutrophils in the bone marrow induced by docetaxel and maintains the level of neutrophils within the normal range.
-
New indications for Hengrui Remazolam Tosylate for Injection are reported on the market
Time of Update: 2021-05-21
On May 13th, the CDE official website showed that Hengrui had submitted a new indication of "remazolam tosylate for injection" for the marketing application and was undertaken by CDE.
-
Shijian Biologics Trop-2 ADC declares the sixth clinical application in China
Time of Update: 2021-05-21
On May 13th, the CDE official website showed that the application for the clinical trial of the recombinant humanized anti-Trop2 monoclonal antibody-SN38 conjugate of Shijian Bio/Toyo Pharmaceutical Co.
At present, there are more than 50 ADC drugs declared clinically in China, involving targets including HER2, TROP-2, CD30, c-Met, etc.
-
UCB IL-17A/F dual inhibitor starts phase 3 clinical trials in China
Time of Update: 2021-05-21
Source: Guanlan PharmaceuticalThe Chinese drug clinical trial registration and information disclosure platform shows that UCB (UCB) has launched a single-arm, international multi-center phase 3 clinical trial of bimekizumab in China for the treatment of active axial spondylitis and ankylosing spine Patients with axial spondyloarthritis with negative inflammation and radiology.
-
Xianju Pharmaceutical's drospirenone and ethinylestradiol tablets (Ⅱ) domestic production drug registration application approved
Time of Update: 2021-05-21
On May 12, Xianju Pharmaceutical issued an announcement stating that it had recently received a notification of acceptance of registration for domestic production of drospirenone and ethinyl estradiol tablets (II) issued by the State Drug Administration.
The reference preparation is the imported original product drospirenone and ethinyl estradiol tablets (II) (trade name: Yousiyue®), which is marketed in China.
-
Lukang Pharmaceutical Cephalexin Tablets Passed Generic Drug Consistency Evaluation
Time of Update: 2021-05-21
In 2020, the domestic sales of cephalexin tablets will be approximately RMB 90 million, and the company's sales revenue of this product will be RMB 5.
